Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts provide insights on the trends, challenges and opportunities for biopharmaceutical companies, including why an interdisciplinary approach is needed to improve outcomes in oncology.
The theme of the 2023 American Society of Clinical Oncology congress, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” highlights the growing cancer care gap preventing significant numbers of patients from benefiting from advancements in prevention, diagnosis, and treatment. These disparities are not due to a lack of innovation—novel approaches to testing and screening have driven an abundance of therapeutics that extend life and, in some cases, promise to cure disease.
However, many patients remain unable to access treatment due to social determinants such as proximity to treatment sites, affordability, lack of transport, age, language barriers, and income status.
As Joseph Mikhael, MD, professor in the Applied Cancer Research and Drug Discovery Division at the Translational Genomics Research Institute in Phoenix, Arizona, noted in a recent interview with Oncology Live, the top barriers driving healthcare disparities are:
- Time to diagnosis
- Time to therapy
- Access to specialized centers
- The four T’s—access to triplets, transplants, trials, and CAR-T
- Physician bias
It will take tenacity and new ways of thinking to solve the deeply ingrained barriers preventing equitable treatment and care, and manufacturers will need to build greater connections across the community to collaborate with a wider range of stakeholders more deeply and earlier on to ensure the patient voice is central to the commercial strategy.
We hope you benefit from our oncology experts’ analysis of the global and North American trends and their recommendations for driving commercial success across a range of stakeholders within the oncology setting. By taking an interdisciplinary approach, and connecting advisory and executional capabilities, we hope to realize the potential of healthcare strategies and solutions that build connections that will result in improved outcomes for cancer patients.
Read on to learn about:
- Driving uptake of biomarker testing among community oncologists
- Integrating patient centricity across the commercialization path in multiple myeloma
- The increasing influence of the Centers for Medicare and Medicaid Services on the commercialization of oncology products
- Why applying a commercial lens to Phase 2 trials will drive launch success
- Advice on commercializing CAR-T therapies—from driving equitable access to developing impactful and relevant marketing
- A case study on determining endpoints in non-small-cell lung cancer